Brief: Knight Therapeutics Announces Filing Of New Drug Submission For Qelbree (Viloxazine) In Canada
16/12/2024 21:41
Dec 16 (Reuters) - Knight Therapeutics Inc GUD.TO :
* KNIGHT THERAPEUTICS ANNOUNCES FILING OF NEW DRUG
SUBMISSION FOR
QELBREE® (VILOXAZINE) IN CANADA
Source text: ID:nGNX2J7l3P
Further company coverage: GUD.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil